Ann: Exclusive Distribution Rights for DuelCap System Secured, page-9

Hey Spartacus

Not hard to tell from your posts you have a soft spot for Analytica. I do too - it was through the Analytica burette that I came to find and know MLA when the distribution deal was done in 2011.

The main selling point of the burette is the saving in nurses time through the autostart feature after the medication has been delivered.  However, there are a couple of other features the inventor was keen to note that usually don’t get a mention -
(1) Once the fluid runs out the float and valve mechanism shuts the line so that no air can get in to the IV set causing an embolism and potentially killing the patient; and
(2) The float mechanism when using the autostart feature means there is constant head pressure and therefore drip rate too.
The reason for these aspects not being highlighted is perhaps that infusion pumps have the capability to detect embolisms and manage flow rates. Nevertheless it’s impressive that a device costing $11 has some of the features of a machine costing thousands.

In terms of sales if we estimate royalties to Analytica at 5% then the royalty payments of $6228 during FY2015 equates to sales of $125K by MLA. This figure wouldn’t be the Autostart (FirstFlow) burette alone, but also include the Tuta burettes with MedifFush feature too (also developed by Analytica). Having invested $3M developing the burette Analytica shareholders are understandably disappointed.

Given the relatively small volume of sales and the patent expiring in 2026 any deal to acquire the IP would seem to be a marginal proposition for both companies.

There is a video demonstrating the setup of the burette for the NSW ambulance service, with the FirstFlow burette shown at the 5:30 mark here -